Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 17c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $196.83 million versus the consensus estimate of $200.09 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Coty (COTY) Misses Q4 EPS by 1c, offers outlook
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance